

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 30 (cancelled)

31 (currently amended): A method for treating an ophthalmic disorder in a mammal, said method comprising administering to the eye of said mammal a lipid formulation, said lipid formulation comprising:

a lipid phase, said lipid phase comprising a phospholipid and a modifying agent, wherein said modifying agent is a ~~member selected from the group consisting of~~ cationic lipid[[s]] ~~and mucoadhesive compounds;~~

an aqueous phase; and

a therapeutic agent, wherein the therapeutic agent is diclofenac, or a pharmaceutically acceptable salt thereof;

wherein said therapeutic agent in said lipid formulation is useful for treating said ophthalmic disorder;

wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase, and wherein said lipid phase comprises 0.1 to 90.0 wt% of the therapeutic agent, 0.01 to ~~10 wt%~~ 98.8 wt% phospholipid, 0.1 to 10 wt % modifying agent and 0.1 to 10 wt% antioxidant.

32 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is post-operative pain.

33 (original): The method in accordance with claim 31, wherein said ophthalmic disorder is ocular inflammation.

1 34 (previously presented): The method in accordance with claim 33, wherein
2 said ocular inflammation results from a member selected from the group consisting of iritis,
3 conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior
4 uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars
5 planitis, ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion
6 and blood-aqueous barrier disruption.

1 35 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is post-operative ocular inflammation.

1 36 (original): The method in accordance with claim 35, wherein said post-
2 operative ocular inflammation results from a member selected from the group consisting of
3 photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial
4 keratotomy.

1 37 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is a fungal or bacterial infection.

1 38 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is herpes ophthalmicus.

1 39 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is endophthalmitis.

1 40 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is intraocular pressure.

41 - 42 (cancelled)

1 43 (currently amended): A method for treating or preventing ocular
2 inflammation, paracentesis-induced miosis, cystoid macular edema and mydriasis, said method
3 comprising administering a therapeutically effective amount of ~~one or more~~ a first non-steroidal

4 anti-inflammatory drug and optionally a second non-steroidal anti-inflammatory drugs
5 encapsulated or contained within a liposome formulation, said liposome formulation comprising
6 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous phase, wherein said lipid
7 phase comprises 0.1 to 90.0 wt% of said first anti-inflammatory drug, 0.01 to 10 wt% 98.8 wt%
8 phospholipid, 0.1 to 10 wt% modifying agents and 0.1 to 10 wt% antioxidant;
9 wherein said modifying agent is a cationic lipid;
10 wherein said first non-steroidal anti-inflammatory drug is diclofenac, or a
11 pharmaceutically acceptable salt thereof.

1 44 (original): The method in accordance with claim 43, wherein said liposome
2 formulation is applied topically, resulting in the transcorneal or transscleral passage or
3 introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

45 - 46 (cancelled)

1 47 (currently amended): The method in accordance with claim 46, wherein said
2 second non-steroidal anti-inflammatory drugs are selected from the group consisting of
3 ketoprofen, flurbiprofen, ibuprofen, ~~diclofenac~~, ketorolac, nepafenac, amfenac and suprofen.

48 (cancelled)

1 49 (previously presented): The method in accordance with claim 43, wherein
2 said ocular inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis,
3 post-operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis
4 associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ocular
5 lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy, corneal abrasion, blood-
6 aqueous barrier disruption or ocular trauma.

1 50 (original): The method in accordance with claim 49, wherein said post-
2 operative inflammation is caused by photorefractive keratectomy, cataract removal surgery,
3 intraocular lens implantation or radial keratotomy.

Appl. No. 10/713,787
Amdt. dated January 30, 2009
Reply to Office Action of December 28, 2007

PATENT

51 - 52 (cancelled)